Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPB2 | Q96IY4 | 14/20 | 0.49 |
| ▸ | CPB1 | P15086 | 7/20 | 0.47 |
| ▸ | ITGB3 | P05106 | 3/20 | 0.40 |
| ▸ | ITGA2B | P08514 | 3/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17044394 | 1.00 | CPB2 (0.49) | CPB2CPB1ITGB3ITGA2B | |
| SCHEMBL22392864 | 1.00 | CPB2 (0.49) | CPB2CPB1ITGB3ITGA2B | |
| SCHEMBL749157 | 1.00 | CPB2 (0.49) | CPB2CPB1ITGB3ITGA2B | |
| SCHEMBL8896989 | 0.99 | CPB2 (0.48) | CPB2CPB1ITGB3ITGA2B | |
| SCHEMBL9110288 | 0.99 | CPB2 (0.48) | CPB2CPB1ITGB3ITGA2B | |
| SCHEMBL5663758 | 0.88 | CPB2 (0.50) | CPB2CPB1ITGB3ITGA2B | |
| SCHEMBL5964769 | 0.88 | CPB2 (0.48) | CPB2CPB1ITGB3ITGA2B | |
| SCHEMBL4393104 | 0.88 | HDAC6 (0.47) | CPB2CPB1 | |
| SCHEMBL5964147 | 0.88 | CPB2 (0.50) | CPB2CPB1ITGB3ITGA2B | |
| SCHEMBL11225379 | 0.87 | CPB2 (0.49) | CPB2CPB1ITGB3ITGA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 632 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026089752-A1 | COMPOSITIONS AND METHODS FOR MICROSPHERE DELIVERY OF THERAPEUTIC PEPTIDES | Finitus, LLC (US) | 2026-04-30 | — | — | WO | claimed |
| US-20260108467-A1 | COMPOSITIONS AND METHODS FOR MICROSPHERE DELIVERY OF THERAPEUTIC PEPTIDES | FINITUS LLC (US) | 2026-04-23 | — | — | US | claimed |
| US-20260108581-A1 | COMPOSITIONS AND METHODS FOR MICROSPHERE DELIVERY OF CARNOSINE FOR TREATMENT OF NEURODEGENERATIVE DISEASES AND DISORDERS | FINITUS LLC (US) | 2026-04-23 | — | — | US | claimed |
| US-20260083658-A1 | Personal Cleansing Composition | BYRNE DANIEL (IE) | 2026-03-26 | — | — | US | claimed |
| US-20260048091-A1 | COMPOSITIONS AND METHODS FOR IMPROVING GASTROINTESTINAL HEALTH IN A SUBJECT | CROSS III WILLIAM H (US) | 2026-02-19 | — | — | US | claimed |
| EP-4696298-A2 | PERSONAL CLEANSING COMPOSITION | Byrne, Daniel (IE) | 2026-02-18 | — | — | EP | claimed |
| EP-4039248-B1 | OPHTHALMIC COMPOSITION | ZAKL FARMACEUTYCZNE POLPHARMA S A (PL) | 2026-01-28 | — | — | EP | claimed |
| US-20260014120-A1 | COMPOSITIONS AND METHODS FOR TOPICAL DELIVERY OF SALTS OF CARNOSINE AND CARNITINE | NeuviDerm LLC (US) | 2026-01-15 | — | — | US | claimed |
| US-20250381240-A1 | COMPOSITIONS AND METHODS FOR HAIR TREATMENT | NEUVIAN SKINCARE LLC (US) | 2025-12-18 | — | — | US | claimed |
| US-20250339545-A1 | ANTIOXIDANT COMPOSITIONS AND METHODS | LEUVIAN LLC (US) | 2025-11-06 | — | — | US | claimed |
| US-20040192647-A1 | topically applying an aqueous ophthalmic composition comprising N-acetylcarnosine, a N-acetylcarnosine derivative and a cellulose compound which increases intraocular absorption of N-acetylcarnosine; a hydrophilic hydrogel contact lens and an ocular polymer insert for topical application | BABIZHAYEV MARK A (RU) | 2004-09-30 | — | — | US | claimed |
| WO-2004028536-A1 | METHOD FOR TOPICAL TREATMENT OF EYE DISEASE AND COMPOSITION AND DEVICE FOR SAID TREATMENT | BABIZHAYEV MARK A (RU) | 2004-04-08 | — | — | WO | claimed |
| US-20040014814-A1 | Compositions and methods for delaying preventing rejuvenating or reversing senescence in cells | BETA PEPTIDE FOUNDATION PTY LTD., THE (AU) | 2004-01-22 | — | — | US | claimed |
| EP-1328620-A1 | COMPOSITIONS AND METHODS FOR DELAYING, PREVENTING, REJUVENATING OR REVERSING SENESCENCE IN CELLS | The Beta Peptide Foundation Pty Ltd (AU) | 2003-07-23 | — | — | EP | claimed |
| US-20030118525-A1 | Treatment of uv induced immunosuppression | GRIGG GEOFFREY WALTER (AU) | 2003-06-26 | — | — | US | claimed |
| EP-1297830-A1 | Use of alpha- or beta-amino acids, of the corresponding esters or of dipeptides of these amino acids with histidine derivatives in the prevention or treatment of tissue damage caused by a atmospheric ozone | Flamma Fabbrica Lombarda Ammino Acidi S.p.a. (IT) | 2003-04-02 | — | — | EP | claimed |
| EP-1248593-A1 | TREATMENT OF UV INDUCED IMMUNOSUPPRESSION | Grigg, Geoffrey Walter (AU) | 2002-10-16 | — | — | EP | claimed |
| WO-2002026940-A1 | COMPOSITIONS AND METHODS FOR DELAYING, PREVENTING, REJUVENATING OR REVERSING SENESCENCE IN CELLS | THE BETA PEPTIDE FOUNDATION PTY LTD (AU) | 2002-04-04 | — | — | WO | claimed |
| WO-2001052808-A1 | TREATMENT OF UV INDUCED IMMUNOSUPPRESSION | GRIGG GEOFFREY WALTER (AU) | 2001-07-26 | — | — | WO | claimed |
| WO-1995010294-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING N-ACETYLCARNOSINE FOR THE TREATMENT OF CATARACT | BRUSCHETTINI S.R.L. (IT) | 1995-04-20 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260108581-A1 | COMPOSITIONS AND METHODS FOR MICROSPHERE DELIVERY OF CARNOSINE FOR TREATMENT OF NEURODEGENERATIVE DISEASES AND DISORDERS | HTT, CLN6, HDAC6 | CPB2 3281/4885CPB1 2866/4885ITGB3 4113/4885 |
| US-20260048091-A1 | COMPOSITIONS AND METHODS FOR IMPROVING GASTROINTESTINAL HEALTH IN A SUBJECT | GSS, GLS, GLS2 | CPB2 292/4885CPB1 303/4885ITGB3 1917/4885 |
| US-20040192647-A1 | topically applying an aqueous ophthalmic composition comprising N-acetylcarnosine, a N-acetylcarnosine derivative and a cellulose compound which increases intraocular absorption of N-acetylcarnosine; a hydrophilic hydrogel contact lens and an ocular polymer insert for topical application | NAT1, B3GNT2, UACA | CPB2 1090/4885CPB1 848/4885ITGB3 2720/4885 |
| US-20250339545-A1 | ANTIOXIDANT COMPOSITIONS AND METHODS | SOD1, SOD3, LPO | CPB2 849/4885CPB1 958/4885ITGB3 1706/4885 |
| US-20260108467-A1 | COMPOSITIONS AND METHODS FOR MICROSPHERE DELIVERY OF THERAPEUTIC PEPTIDES | FGF23, FIBP, PTMS | CPB2 2203/4885CPB1 1499/4885ITGB3 2932/4885 |
| US-20260083658-A1 | Personal Cleansing Composition | S100P, S100B, S100A8 | CPB2 374/4885CPB1 542/4885ITGB3 4785/4885 |
| US-20260014120-A1 | COMPOSITIONS AND METHODS FOR TOPICAL DELIVERY OF SALTS OF CARNOSINE AND CARNITINE | CRAT, CCR10, SLC25A20 | CPB2 3840/4885CPB1 3501/4885ITGB3 3004/4885 |
| US-20250381240-A1 | COMPOSITIONS AND METHODS FOR HAIR TREATMENT | AOC1, SOD3, OAT | CPB2 1744/4885CPB1 1244/4885ITGB3 3217/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.